Association Between Early Idiopathic Neonatal Jaundice and Urinary Tract Infections

Murat Özcan¹, S Ümit Sarici¹, Yüksel Yurdugül¹, Melis Akpinar¹, Demet Altun¹, Begüm Özcan², Muhittin A Serdar³ and Dilek Sarici⁴

¹Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Ufuk University, Ankara, Turkey. ²Department of Family Physicians, Ankara Training and Research Hospital, Ankara, Turkey. ³Department of Biochemistry, Faculty of Medicine, Acibadem University, Ankara, Turkey. ⁴Division of Neonatology, Department of Pediatrics, Kecioren Education and Research Hospital, Ankara, Turkey.

Clinical Medicine Insights: Pediatrics Volume 11: 1-7 © The Author(s) 2017 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1179556517701118



ABSTRACT

BACKGROUND AND PURPOSE: Etiologic role, incidence, demographic, and response-to-treatment characteristics of urinary tract infection (UTI) among neonates, its relationship with significant neonatal hyperbilirubinemia, and abnormalities of the urinary system were studied in a prospective investigation in early (<10 days) idiopathic neonatal jaundice in which all other etiologic factors of neonatal hyperbilirubinemia were ruled out.

PATIENTS AND METHODS: Urine samples for microscopic and bacteriologic examination were obtained with bladder catheterization from 155 newborns with early neonatal jaundice. Newborns with a negative urine culture and with a positive urine culture were defined as group I and group II, respectively, and the 2 groups were compared with each other.

RESULTS: The incidence of UTI in whole of the study group was 16.7%. Serum total and direct bilirubin levels were statistically significantly higher in group II when compared with group I (P = .005 and P = .001, respectively). Decrease in serum total bilirubin level at the 24th hour of phototherapy was statistically significantly higher in group I compared with group II (P = .022).

CONCLUSIONS: Urinary tract infection should be investigated in the etiologic evaluation of newborns with significant hyperbilirubinemia. The possibility of UTI should be considered in jaundiced newborns who do not respond to phototherapy well or have a prolonged duration of phototherapy treatment.

KEYWORDS: Newborn, early jaundice, urinary tract infection, significant hyperbilirubinemia

RECEIVED: November 8, 2016, ACCEPTED: March 3, 2017.

PEER REVIEW: Four peer reviewers contributed to the peer review report. Reviewers reports totaled 1434 words, excluding any confidential comments to the academic editor.

TYPE: Original Research

FUNDING: The author(s) received no financial support for the research, authorship, and/or publication of this article.

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article

CORRESPONDING AUTHOR: Demet Altun, Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Ufuk University, Balgat 06520, Ankara, Turkey. Email: draltundemet@gmail.com

Introduction

Indirect (unconjugated) hyperbilirubinemia, which is seen in 60% to 80% of newborns in the first days of life, may be one of the first signs of a serious bacterial infection.¹ This type of jaundice may reportedly be an important and even the first presenting sign of urinary tract infection (UTI).² The physiopathologic relationship between neonatal jaundice and UTI has always gained much interest and recently been investigated in various studies. However, this relationship has been preferably studied in newborns with late (\geq 8 days) jaundice,³⁻⁶ prolonged jaundice $(\geq 15 \text{ days})$,^{5,7–9} or conjugated hyperbilirubinemia,⁵ and only few studies among newborns with early (≤ 7 days) jaundice have been conducted.^{2,10,11} Currently, authorized international institutions, such as American Academy of Pediatrics, do not recommend investigation of UTI with urinalysis or urine culture as part of investigations for the etiology of either early or late/prolonged neonatal jaundice.12

In this study, etiologic role, prevalence, demographic, and response-to-treatment characteristics of UTI among neonates, its relationship with significant neonatal hyperbilirubinemia, and abnormalities of the urinary system were studied in a prospective investigation in early (≤ 10 days) idiopathic neonatal jaundice in which all other etiologic factors of neonatal hyperbilirubinemia were ruled out.

Patients and Methods

This study was conducted at the Division of Neonatology, Department of Pediatrics of Ufuk University Faculty of Medicine between June 2015 and August 2016. All newborns who were diagnosed with significant hyperbilirubinemia and required phototherapy treatment were included in the study. With the aim to determine whether UTI was the cause of pathologic jaundice, urine samples for microscopic and bacteriologic examination were obtained via bladder catheterization in all cases.

The diagnosis of significant hyperbilirubinemia was made considering gestational and postnatal age and risk factors of the

 Θ

newborns,^{12,13} and these cases were put on phototherapy. Late preterm, early term, and term newborns were included in the study, and newborns with a gestational age of less than 35 weeks were not included as the prematurity itself is a major risk factor in the etiology of hyperbilirubinemia.

As the primary aim of the study was to determine whether UTI itself was the leading cause in the etiology of significant hyperbilirubinemia, newborns with isoimmunization (ABO, Rh, or subgroup incompatibilities), direct Coombs test positivity, findings of hemolysis on blood smear (anisocytosis, spherocytosis, polychromasia, poikilocytosis), anemia, reticulocytosis, and/or glucose-6-phosphate dehydrogenase deficiency were excluded from the study. Other exclusion criteria were the presence of any major congenital anomaly, respiratory distress, and clinical or culture-proven sepsis.

The study was conducted according to clinical practice guidelines and approved by the local ethics committee. Informed consent was obtained from any parents of each patient. Parents were questioned in detail regarding their baby's clinical signs and symptoms other than jaundice, such as fever, lethargy, irritability, diarrhea, feeding intolerance (poor feeding, vomiting), poor weight gain, or dirty skin color (poor tissue perfusion).

In all cases (diagnosed to have significant hyperbilirubinemia), sex; birth weight; route of delivery; maternal age; gestational age; postnatal age (as hours) on admission; weight on admission; weight loss as percent in comparison with birth weight; abnormal weight loss defined as the loss of body weight more than 7% and 12% on the fourth and seventh days of life, respectively¹⁴; feeding pattern; whether there was enclosed hemorrhage; blood groups and Rh types in mother-infant pairs; hemoglobin and hematocrit levels; number of white blood cells; ratio of immature-to-total neutrophils on peripheral blood smear; results of reticulocyte count and direct antiglobulin test; level of C-reactive protein; serum total and direct bilirubin levels measured with colorimetric method (diazotized sulfanilic acid reaction; Roche Diagnostics GmbH, Mannheim, Germany); renal function tests (blood urea nitrogen and creatinine); free T_4 and thyroid-stimulating hormone (TSH) levels; results of blood gases examination, if needed; glucose-6-phosphate dehydrogenase levels; whether there was any growth in urine culture and types and amounts of microorganism(s); and results of microscopic examination of urine (whether pyuria was present or not) were recorded. No further detailed tests were done toward demonstrating the etiology of hyperbilirubinemia in newborns with both significant hyperbilirubinemia and UTI.

Bladder catheterization was performed with aseptic technique after feeding and fixation of the infant. In all cases in whom phototherapy was started, serum total and direct bilirubin levels were measured at the 24th hour of phototherapy to evaluate the response to treatment and make the decision to stop treatment, and decrease in serum total bilirubin levels at the 24th hour of phototherapy was recorded as percentage decrease. Urine samples were sent immediately to microbiology laboratory for standard quantitative culture, and growth of single type microorganism on culture medium with an amount of at least 1000 CFU/mL was accepted as UTI.¹⁵ Renal ultrasonography was performed on all newborns with UTI, and voiding cystoureterography (after obtaining a sterile urine culture, approximately 1 month after the diagnosis) and dimercaptosuccinic acid scintigraphy (3 months after the diagnosis) were performed on those with any abnormality on renal ultrasonography.

In the initial analysis of the data prevalence of UTI as the cause of significant hyperbilirubinemia was determined. Later on, newborns with significant hyperbilirubinemia but without UTI and newborns with both significant hyperbilirubinemia and UTI were classified as group I and group II, respectively, and these groups were compared regarding demographic, laboratory, radiological, and microbiological characteristics.

SPSS 18.0 program was used in statistical analysis of data. Kolmogorov-Smirnov test was used in determining normal distribution. Nominal values, such as sex, route of delivery, presence or absence of pyuria, and feeding pattern, were compared with χ^2 and Fisher exact χ^2 tests. Of continuously variable parameters, gestational age, age on admission, and serum direct (conjugated) bilirubin levels were compared with Mann-Whitney *U* test, and maternal age, birth weight, weight on admission, levels of serum total bilirubin, free T₄, TSH, hemoglobin, hematocrit, and serum bilirubin at 24th hour were compared with independent sample *t* test. Decrease in serum total bilirubin level at 24th hour calculated as percent was compared between the groups using Mann-Whitney *U* test. Values were given as mean \pm SD. A *P* value of \leq .05 was considered statistically significant.

Results

The study was started with 188 newborns. However, parents of 12 newborns did not want to participate in the study, 21 newborns were excluded as they had exclusion criteria, and a total of 155 newborns with significant hyperbilirubinemia were finally included in the study during the study period. Mean gestational age and age on admission of these newborns were 37.7 ± 1.5 weeks and 126.6 ± 58.8 hours, respectively. Mean birth weight and weight on admission were 3141.1 ± 499.7 and 2978.3 ± 462.1 g, respectively, and weight loss on admission was -5.11 ± 3.64%. On admission, serum total and direct bilirubin levels were 18.55 ± 2.98 and 0.56 ± 0.15 mg/dL, respectively, and serum total bilirubin level at the 24th hour of phototherapy was 9.03 ± 1.54 mg/dL with a 51.2 ± 3.96% decrease. In all these cases, phototherapy was administered, and no other treatment modalities, such as exchange transfusion and intravenous immunoglobulin administration, were needed.

Urinary tract infection was detected in 26 (16.7%) of the 155 newborns included. Of these, 3 (11.5%) and 23 (88.5%) were women and men, respectively, and causative agents were *Klebsiella* spp. (8 of 26: 30.76%), *Enterococcus* spp. (7 of 26:

21262910Male1000 Staphylococus19.9Normal61622100Rana5000 Klobiella sp.15.2Normal71203200Female1000 Excherichi coli3.3Normal8783200Male1000 Excherichi coli7.4Normal10793450Male1000 Excherichi coli24.1Normal112362500Male1000 Excherichi coli7.9Normal121223150Male1000 Excherichi coli7.9Normal14483770Male1000 Staphylococus7.9Normal15963370Male5000 Excherichiccus19.6Normal161523850Male5000 Staphylococus19.4Normal171074000Male5000 Staphylococus19.4Normal18543700Male5000 Staphylococus19.4Normal191621630Male1000 Staphylococus19.4Normal1016430001000 Staphylococus19.4Normal10.0192643600Male1000 Staphylococus19.4Normal101621600Male1000 Staphylococus19.4Normal12763500Male1000 Staphylococus19.4Normal14180016001000 Staphylococus19.4Normal15 <td< th=""><th>CASE</th><th>AGE ON ADMISSION, H</th><th>BIRTH WEIGHT, G</th><th>SEX</th><th>GROWING MICROORGANISM ON URINE CULTURE AND ITS AMOUNT, CFU/ML</th><th>SERUM TOTAL BILIRUBIN, MG/DLª</th><th>ABNORMALITY ON RENAL ULTRASONOGRAPHY</th></td<>	CASE	AGE ON ADMISSION, H	BIRTH WEIGHT, G	SEX	GROWING MICROORGANISM ON URINE CULTURE AND ITS AMOUNT, CFU/ML	SERUM TOTAL BILIRUBIN, MG/DLª	ABNORMALITY ON RENAL ULTRASONOGRAPHY
120 3260 Female 10 000 Escherichia coli 23.9 Normal 8 78 3260 Male 100 000 Enterococcus 17.4 Normal 10 79 3450 Male 10000 E coli 24.1 Normal 11 236 2500 Male 10000 E coli 18 Normal 12 122 3150 Male 2000 Staphylococcus 20 Normal 14 48 3770 Male 100 000 Enterococcus 19.6 Normal 15 96 3370 Male 5000 Klebsiella spp. 19.9 Normal 16 152 3850 Male 5000 Klebsiella spp. 19.9 Normal 17 107 4000 Male 3000 Enterococcus 21.4 Normal 18 54 3700 Female 3000 Enterococcus 24.9 Normal 20 216 200 Male 100 000 Klebsiella spp. 17.3 Normal <td< td=""><td>2</td><td>126</td><td>2910</td><td>Male</td><td>100 000 Staphylococcus</td><td>19.9</td><td>Normal</td></td<>	2	126	2910	Male	100 000 Staphylococcus	19.9	Normal
8783260Male100 000 Enterococcus17.4Normal10793450Male10 000 E coli24.1Normal112362500Male100 000 E coli18Normal121223150Male20 000 Staphylococcus20Normal14483770Male100 000 Staphylococcus17.9Normal15963370Male50 000 Enterococcus19.6Normal161523850Male50 000 Klebsiella spp.19.9Normal171074000Male30 000 Enterococcus24.4Normal18543700Female30 000 Enterococcus21.4Normal191624160Male30 000 Enterococcus24.9Normal202162000Male100 000 Klebsiella spp.20.6Normal21763200Male100 000 Klebsiella spp.17.3Normal22763200Male100 000 Klebsiella spp.17.3Normal231763600Male100 000 Enterococcus18.4Normal24983200Male100 000 Enterococcus19.5Normal25663530Male100 000 Enterococcus19.5Normal261443150Male100 000 Enterococcus19.5Normal261443150Male100 000 Enterococcus19.5 <td< td=""><td>6</td><td>162</td><td>2110</td><td>Male</td><td>50 000 Klebsiella spp.</td><td>15.2</td><td>Normal</td></td<>	6	162	2110	Male	50 000 Klebsiella spp.	15.2	Normal
10 79 3450 Male 10 000 E coli 24.1 Normal 11 236 2500 Male 100 000 E coli 18 Normal 12 122 3150 Male 20 000 Staphylococcus 20 Normal 14 48 3770 Male 100 000 Etaphylococcus 17.9 Normal 15 96 3370 Male 50 000 Etaphylococcus 19.6 Normal 16 152 3850 Male 50 000 Klebsiella spp. 19.9 Normal 17 107 4000 Male 100 000 Staphylococcus 21.4 Normal 18 54 3700 Female 30 000 Etherococcus 24.9 Normal 19 162 4160 Male 100 000 Klebsiella spp. 21.4 Normal 20 216 2000 Male 100 000 Klebsiella spp. 17.3 Normal 21 76 3200 Male 100 000 Klebsiella spp. 17.3 No	7	120	3260	Female	10 000 Escherichia coli	23.9	Normal
11 236 2500 Male 100 000 E coli 18 Normal 12 122 3150 Male 20 000 Staphylococcus 20 Normal 14 48 3770 Male 100 000 Staphylococcus 17.9 Normal 15 96 3370 Male 50 000 Enterococcus 19.6 Normal 16 152 3850 Male 50 000 Staphylococcus 21.4 Normal 17 107 4000 Male 30 000 Straphylococcus 24.9 Normal 18 54 3700 Female 30 000 Enterococcus 24.9 Normal 19 162 4160 Male 100 000 Klebsiella spp. 20.6 Normal 20 216 2000 Male 100 000 Klebsiella spp. 23.0 Normal 21 76 3200 Male 100 000 Klebsiella spp. 23.0 Normal 22 76 3200 Male 100 000 Klebsiella spp. 23.0	8	78	3260	Male	100 000 Enterococcus	17.4	Normal
121223150Male20 000 Staphylococcus20Normal14483770Male100 000 Staphylococcus17.9Normal15963370Male50 000 Enterococcus19.6Normal161523850Male50 000 Klebsiella spp.19.9Normal171074000Male100 000 Staphylococcus21.4Normal18543700Female30 000 Enterococcus13.4Normal191624160Male30 000 Enterococcus24.9Normal202162000Male100 000 Klebsiella spp.20.6Normal21763200Male100 000 Klebsiella spp.17.3Normal231763600Male100 000 Klebsiella spp.17.3Normal24983200Male100 000 Staphylococcus16.1Normal25663530Male100 000 Enterococcus19.5Normal261443150Male100 000 Klebsiella spp.20.7Left pelviectasis3993680Male100 000 Klebsiella spp.18.4Unilateral cortical cyst41683240Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral renal pelviess51214170Male100 000 Klebsiella spp.20.7Left pelviectasis593660Male100 000 Klebsiella spp.20.6 <t< td=""><td>10</td><td>79</td><td>3450</td><td>Male</td><td>10 000 <i>E coli</i></td><td>24.1</td><td>Normal</td></t<>	10	79	3450	Male	10 000 <i>E coli</i>	24.1	Normal
14483770Male100 000 Staphylococcus17.9Normal15963370Male50 000 Enterococcus19.6Normal161523850Male50 000 Klebsiella spp.19.9Normal171074000Male100 000 Staphylococcus21.4Normal18543700Female30 000 Streptococcus13.4Normal191624160Male30 000 Enterococcus24.9Normal202162000Male100 000 Klebsiella spp.20.6Normal21763200Male100 000 Enterococcus20.2Normal231763600Male100 000 Klebsiella spp.17.3Normal24983200Male100 000 Staphylococcus16.1Normal25663530Male100 000 Enterococcus19.5Normal261443150Male100 000 Klebsiella spp.20.7Left pelviectasis3993680Male100 000 Klebsiella spp.20.7Left pelviectasis41683240Male100 000 Enterococcus24.7Left pelviectasis51214170Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral renal pelvises9963060Male100 000 Ecoli23.3Left hydronephrosis91013000Male100 000 Ecoli23.7Bilateral pelviec	11	236	2500	Male	100 000 <i>E coli</i>	18	Normal
15 96 3370 Male 50 000 Enterococcus 19.6 Normal 16 152 3850 Male 50 000 Klebsiella spp. 19.9 Normal 17 107 4000 Male 100 000 Staphylococcus 21.4 Normal 18 54 3700 Female 30 000 Enterococcus 13.4 Normal 19 162 4160 Male 30 000 Enterococcus 24.9 Normal 20 216 2000 Male 100 000 Enterococcus 20.2 Normal 21 76 3200 Male 100 000 Enterococcus 20.2 Normal 23 176 3600 Male 100 000 Klebsiella spp. 17.3 Normal 24 98 3200 Male 100 000 Staphylococcus 16.1 Normal 25 66 3530 Male 100 000 Enterococcus 19.5 Normal 26 144 3150 Male 100 000 Klebsiella spp. 20.7	12	122	3150	Male	20 000 Staphylococcus	20	Normal
16 152 3850 Male 50 000 Klebsiella spp. 19.9 Normal 17 107 4000 Male 100 000 Staphylococcus 21.4 Normal 18 54 3700 Female 30 000 Streptococcus 13.4 Normal 19 162 4160 Male 30 000 Enterococcus 24.9 Normal 20 216 2000 Male 100 000 Klebsiella spp. 20.6 Normal 21 76 3200 Male 100 000 Klebsiella spp. 20.2 Normal 23 176 3600 Male 100 000 Klebsiella spp. 23 Normal 24 98 3200 Male 100 000 Staphylococcus 16.1 Normal 25 66 3530 Male 100 000 Enterococcus 19.5 Normal 26 144 3150 Male 100 000 Klebsiella spp. 20.7 Left pelviectasis 3 99 3680 Male 100 000 Klebsiella spp.	14	48	3770	Male	100 000 Staphylococcus	17.9	Normal
171074000Male100 000 Staphylococcus21.4Normal18543700Female30 000 Streptococcus13.4Normal191624160Male30 000 Enterococcus24.9Normal202162000Male100 000 Klebsiella spp.20.6Normal22763200Male100 000 Enterococcus20.2Normal231763600Male100 000 Klebsiella spp.17.3Normal24983200Male50 000 Klebsiella spp.23Normal25663530Male100 000 Enterococcus16.1Normal261443150Male100 000 Enterococcus19.5Normal12392830Female30 000 Klebsiella spp.20.7Left pelviectasis3993680Male100 000 Enterococcus24.7Left pelviectasis51214170Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral cortical cyst9963060Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral renal pelvises9963060Male100 000 Klebsiella spp.23.3Left hydronephrosis1193900Male100 000 Klebsiella spp.23.7Bilateral pelvisetasis	15	96	3370	Male	50 000 Enterococcus	19.6	Normal
18 54 3700 Female 30 000 Streptococcus 13.4 Normal 19 162 4160 Male 30 000 Enterococcus 24.9 Normal 20 216 2000 Male 100 000 Klebsiella spp. 20.6 Normal 22 76 3200 Male 100 000 Enterococcus 20.2 Normal 23 176 3600 Male 100 000 Klebsiella spp. 17.3 Normal 24 98 3200 Male 50 000 Klebsiella spp. 23 Normal 25 66 3530 Male 100 000 Enterococcus 16.1 Normal 26 144 3150 Male 100 000 Enterococcus 19.5 Normal 1 239 2830 Female 30 000 Klebsiella spp. 20.7 Left pelviectasis 3 99 3680 Male 100 000 Enterococcus 24.7 Left pelviectasis 5 121 4170 Male 100 000 Klebsiella spp.	16	152	3850	Male	50 000 Klebsiella spp.	19.9	Normal
19 162 4160 Male 30 000 Enterococcus 24.9 Normal 20 216 2000 Male 100 000 Klebsiella spp. 20.6 Normal 22 76 3200 Male 100 000 Enterococcus 20.2 Normal 23 176 3600 Male 100 000 Klebsiella spp. 17.3 Normal 24 98 3200 Male 50 000 Klebsiella spp. 23 Normal 25 66 3530 Male 100 000 Enterococcus 16.1 Normal 26 144 3150 Male 100 000 Enterococcus 19.5 Normal 1 239 2830 Female 30 000 Klebsiella spp. 20.7 Left pelviectasis 3 99 3680 Male 100 000 Enterococcus 24.7 Left pelviectasis 5 121 4170 Male 100 000 Klebsiella spp. 20.6 Minimal dilatation in bilateral renal pelvises 9 96 3060 Male 100 000 E coli 23.3 Left hydronephrosis 119 900	17	107	4000	Male	100 000 Staphylococcus	21.4	Normal
20 216 2000 Male 100 000 Klebsiella spp. 20.6 Normal 22 76 3200 Male 100 000 Enterococcus 20.2 Normal 23 176 3600 Male 100 000 Klebsiella spp. 17.3 Normal 24 98 3200 Male 50 000 Klebsiella spp. 23 Normal 25 66 3530 Male 100 000 Enterococcus 16.1 Normal 26 144 3150 Male 100 000 Enterococcus 19.5 Normal 1 239 2830 Female 30 000 Klebsiella spp. 20.7 Left pelviectasis 3 99 3680 Male 100 000 Enterococcus 24.7 Left pelviectasis 4 168 3240 Male 100 000 Klebsiella spp. 20.6 Minimal dilatation in bilateral renal pelvises 5 121 4170 Male 100 000 E coli 23.3 Left hydronephrosis 9 96 3060 Male <td>18</td> <td>54</td> <td>3700</td> <td>Female</td> <td>30 000 Streptococcus</td> <td>13.4</td> <td>Normal</td>	18	54	3700	Female	30 000 Streptococcus	13.4	Normal
22 76 3200 Male 100 000 Enterococcus 20.2 Normal 23 176 3600 Male 100 000 Klebsiella spp. 17.3 Normal 24 98 3200 Male 50 000 Klebsiella spp. 23 Normal 25 66 3530 Male 100 000 Enterococcus 16.1 Normal 26 144 3150 Male 100 000 Enterococcus 19.5 Normal 1 239 2830 Female 30 000 Klebsiella spp. 20.7 Left pelviectasis 3 99 3680 Male 100 000 Enterococcus 24.7 Left pelviectasis 4 168 3240 Male 100 000 Klebsiella spp. 20.6 Minimal dilatation in bilateral renal pelvises 5 121 4170 Male 100 000 E coli 23.3 Left hydronephrosis 9 96 3060 Male 100 000 E coli 23.7 Bilateral pelviectasis	19	162	4160	Male	30 000 Enterococcus	24.9	Normal
23 176 3600 Male 100 000 Klebsiella spp. 17.3 Normal 24 98 3200 Male 50 000 Klebsiella spp. 23 Normal 25 66 3530 Male 100 000 Staphylococcus 16.1 Normal 26 144 3150 Male 100 000 Enterococcus 19.5 Normal 1 239 2830 Female 30 000 Klebsiella spp. 20.7 Left pelviectasis 3 99 3680 Male 100 000 Enterococcus 24.7 Left pelviectasis 4 168 3240 Male 100 000 Enterococcus 24.7 Left pelviectasis 5 121 4170 Male 100 000 Enterococcus 24.7 Left pelviectasis 9 96 3060 Male 100 000 Ecoli 23.3 Left hydronephrosis 13 119 3900 Male 30 000 Staphylococcus 23.7 Bilateral pelviectasis	20	216	2000	Male	100 000 Klebsiella spp.	20.6	Normal
24 98 3200 Male 50 000 Klebsiella spp. 23 Normal 25 66 3530 Male 100 000 Staphylococcus 16.1 Normal 26 144 3150 Male 100 000 Enterococcus 19.5 Normal 1 239 2830 Female 30 000 Klebsiella spp. 20.7 Left pelviectasis 3 99 3680 Male 100 000 Enterococcus 24.7 Left pelviectasis 4 168 3240 Male 100 000 Klebsiella spp. 20.6 Minimal dilatation in bilateral renal pelvises 5 121 4170 Male 100 000 E coli 23.3 Left hydronephrosis 13 119 3900 Male 30 000 Staphylococcus 23.7 Bilateral pelviectasis	22	76	3200	Male	100 000 Enterococcus	20.2	Normal
25663530Male100 000 Staphylococcus16.1Normal261443150Male100 000 Enterococcus19.5Normal12392830Female30 000 Klebsiella spp.20.7Left pelviectasis3993680Male100 000 Enterococcus24.7Left pelviectasis41683240Male100 000 Enterococcus24.7Left pelviectasis51214170Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral renal pelvises9963060Male100 000 E coli23.3Left hydronephrosis131193900Male30 000 Staphylococcus23.7Bilateral pelviectasis	23	176	3600	Male	100 000 Klebsiella spp.	17.3	Normal
261443150Male100 000 Enterococcus19.5Normal12392830Female30 000 Klebsiella spp.20.7Left pelviectasis3993680Male100 000 Klebsiella spp.18.4Unilateral cortical cyst41683240Male100 000 Enterococcus24.7Left pelviectasis51214170Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral renal pelvises9963060Male100 000 E coli23.3Left hydronephrosis131193900Male30 000 Staphylococcus23.7Bilateral pelviectasis	24	98	3200	Male	50 000 Klebsiella spp.	23	Normal
12392830Female30 000 Klebsiella spp.20.7Left pelviectasis3993680Male100 000 Klebsiella spp.18.4Unilateral cortical cyst41683240Male100 000 Enterococcus24.7Left pelviectasis51214170Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral renal pelvises9963060Male100 000 E coli23.3Left hydronephrosis131193900Male30 000 Staphylococcus23.7Bilateral pelviectasis	25	66	3530	Male	100 000 Staphylococcus	16.1	Normal
3993680Male100 000 Klebsiella spp.18.4Unilateral cortical cyst41683240Male100 000 Enterococcus24.7Left pelviectasis51214170Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral renal pelvises9963060Male100 000 E coli23.3Left hydronephrosis131193900Male30 000 Staphylococcus23.7Bilateral pelviectasis	26	144	3150	Male	100 000 Enterococcus	19.5	Normal
41683240Male100 000 Enterococcus24.7Left pelviectasis51214170Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral renal pelvises9963060Male100 000 E coli23.3Left hydronephrosis131193900Male30 000 Staphylococcus23.7Bilateral pelviectasis	1	239	2830	Female	30 000 Klebsiella spp.	20.7	Left pelviectasis
51214170Male100 000 Klebsiella spp.20.6Minimal dilatation in bilateral renal pelvises9963060Male100 000 E coli23.3Left hydronephrosis131193900Male30 000 Staphylococcus23.7Bilateral pelviectasis	3	99	3680	Male	100 000 Klebsiella spp.	18.4	Unilateral cortical cyst
9963060Male100 000 <i>E coli</i> 23.3Left hydronephrosis131193900Male30 000 <i>Staphylococcus</i> 23.7Bilateral pelviectasis	4	168	3240	Male	100 000 Enterococcus	24.7	Left pelviectasis
131193900Male30 000 Staphylococcus23.7Bilateral pelviectasis	5	121	4170	Male	100 000 <i>Klebsiella</i> spp.	20.6	
	9	96	3060	Male	100 000 <i>E coli</i>	23.3	Left hydronephrosis
21403690Male100 000 Enterococcus18.4Right renal solid cyst	13	119	3900	Male	30 000 Staphylococcus	23.7	Bilateral pelviectasis
	21	40	3690	Male	100 000 Enterococcus	18.4	Right renal solid cyst

Table 1. Demographic and laboratory characteristics of newborns with significant hyperbilirubinemia and diagnosed to have urinary tract infection (n = 26).

^a1 mg/dL bilirubin = 17.1 μ mol/L bilirubin.

26.92%), *Staphylococcus* spp. (6 of 26: 23.07%), *Escherichia coli* (4 of 26: 15.38%), and *Streptococcus* spp. (1 of 26: 3.84%). None of the cases with UTI was circumcised. On ultrasonographic examination, an abnormality was detected in 7 (26.9%) of the 26 newborns diagnosed to have UTI, although most of these were benign in nature; 6 of these 7 newborns were men, and no vesicoureteral reflux of grade \geq 3 or renal scar was detected in any of these patients. Demographic and laboratory characteristics of newborns with significant hyperbilirubinemia and diagnosed to have UTI are given in Table 1, and characteristics of

patients with renal ultrasonographic abnormality are given in the second half of the table.

Detailed clinical signs and symptoms, laboratory abnormalities, and treatment modalities of newborns with both significant hyperbilirubinemia and UTI are given in Table 2.

Comparison of demographic and laboratory characteristics of newborns with significant hyperbilirubinemia but without UTI (group I) and of newborns with both significant hyperbilirubinemia and UTI (group II) is given in Table 3. There were no statistically significant differences

1Fever, jaundiceBlood culture - gyuria (46 white blood cult get)StelleTeicoplanin IV2Feeding intolerance, jaundiceHigh BUNCre (50 mg/dL/0.7 mg/dL, high)StelleCelotaxime IV + FR3JaundiceHigh serum bilirubin level (12.4 mg/dL)SterleCelotaxime IV + FR4JaundiceHigh serum bilirubin level (12.4 mg/dL)SterleCelotaxime IV + FR5JaundiceHigh serum bilirubin level (2.7 mg/dL)SterleCelotaxime IV6JaundiceHigh serum bilirubin level (2.4 mg/dL)SterleCelotaxime IV7JaundiceHigh serum bilirubin level (2.3 mg/dL)SterleCelotaxime IV7JaundiceHigh serum bilirubin level (2.3 mg/dL)SterleTeicoplanin IV8Fever, jaundiceHigh serum bilirubin level (2.3 mg/dL)SterleTeicoplanin IV9JaundiceHigh serum bilirubin level (2.3 mg/dL)SterleTeicoplanin IV10JaundiceHigh serum bilirubin level (2.3 mg/dL)SterleTeicoplanin IV11JaundiceHigh serum bilirubin level (2.4 mg/dL)SterleCelotaxime IV + FR12JaundiceHigh serum bilirubin level (2.4 mg/dL)SterleCelotaxime IV13JaundiceHigh serum bilirubin level (2.4 mg/dL)SterleCelotaxime IV14JaundiceHigh serum bilirubin level (2.4 mg/dL)SterleCelotaxime IV15JaundiceHigh serum bilirubin level (2.4 mg/dL)SterleCelotaxime IV16Jaundice	CASE	COMPLAINTS (OF THE PARENTS) AND POSITIVE CLINICAL SIGNS AND SYMPTOMS	POSITIVE LABORATORY ABNORMALITIES	REPEAT (CONTROL) CULTURE (URINE/ BLOOD)ª	TREATMENT
jaundicejaundicesarum bilirubin level (19.9 mg/dL)SterileCefotaxime IV3JaundiceHigh serum bilirubin level (19.4 mg/dL)SterileCefotaxime IV4Jaundiceserum bilirubin level (20.5 mg/dL)SterileCefotaxime IV5JaundiceHigh serum bilirubin level (20.5 mg/dL)SterileCefotaxime IV6Feeding intolerance, jaundiceHigh serum bilirubin level (23.9 mg/dL)SterileCefotaxime IV8Feeding intolerance, jaundiceHigh serum bilirubin level (23.9 mg/dL)SterileTeicoplanin IV8Feeding intolerance, jaundiceHigh Serum bilirubin level (23.9 mg/dL)SterileTeicoplanin IV9JaundiceHigh Serum bilirubin level (23.9 mg/dL)SterileTeicoplanin IV10Poor weight gain, jaundie serum bilirubin level (24.1 mg/dL), high // ratio serum bilirubin level (24.1 mg/dL)SterileTeicoplanin IV11JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileTeicoplanin IV12JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV + FR13JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV14JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV16JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin	1	Fever, jaundice		Sterile	Teicoplanin IV
4JaundicePyuria (22 white blood cell per HPF), high serum bilirubin level (24.7 mg(dL)SterileTeicoplanin IV5JaundiceHigh serum bilirubin level (26.6 mg/dL)SterileCefotaxime IV6Feeding incloreance, andriceHigh serum bilirubin level (23.9 mg/dL)SterileCefotaxime IV7JaundiceHigh serum bilirubin level (23.9 mg/dL)SterileTeicoplanin IV8Fever, jaundiceHigh serum bilirubin level (23.9 mg/dL)SterileTeicoplanin IV9JaundiceHigh serum bilirubin level (23.3 mg/dL)SterileTeicoplanin IV10Poor weight gain, jaundiceHigh serum bilirubin level (23.3 mg/dL), high bilrubin level (24.1 mg/dL), highSterileTeicoplanin IV11JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileTeicoplanin IV12JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileTeicoplanin IV13Lethargy + rirubability, JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileTeicoplanin IV14JaundiceHigh serum bilirubin level (24.7 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileTeicoplanin IV14JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (14.4 mg/dL)SterileCefotaxime IV17<	2	-		Sterile	Cefotaxime IV + FR
Serium bilirubin level (24.7 mg/dL)Max5JaundiceHigh serum bilirubin level (26.6 mg/dL)SterileCefotaxime IV6Feeding infolerance, andriceHigh serum bilirubin level (15.2 mg/dL)SterileCefotaxime IV7JaundiceHigh serum bilirubin level (23.9 mg/dL)SterileTeicoplanin IV8Fever, jaundiceHigh serum bilirubin level (23.3 mg/dL)SterileTeicoplanin IV9JaundiceHigh serum bilirubin level (23.3 mg/dL), high //T ratio (0.4), high serum bilirubin level (24.1 mg/dL), highSterileTeicoplanin IV10Poor weight gain, jaundiceHigh serum bilirubin level (24.1 mg/dL), highSterileTeicoplanin IV11JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileTeicoplanin IV12JaundiceHigh serum bilirubin level (20.9 mg/dL)SterileTeicoplanin IV13Lethargy + irritability, jaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV14JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (24.1 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileCefotaxime IV18JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileCefotaxime IV19JaundiceHigh serum bilirubin level (24.9 mg/dL) <td< td=""><td>3</td><td>Jaundice</td><td>High serum bilirubin level (18.4 mg/dL)</td><td>Sterile</td><td>Cefotaxime IV</td></td<>	3	Jaundice	High serum bilirubin level (18.4 mg/dL)	Sterile	Cefotaxime IV
6Feeding intolerance, jaundiceHigh serum bilirubin level (15.2 mg/dL)SterileCefotaxime IV7JaundiceHigh serum bilirubin level (23.9 mg/dL)SterileTeicoplanin IV8Fever, jaundiceHigh CRP level (24.1 mg/dL), high //T ratio, (04), high serum bilirubin level (17.4 mg/dL)SterileTeicoplanin IV9JaundiceHigh serum bilirubin level (23.9 mg/dL), bigh //T ratio, (04), high serum bilirubin level (23.1 mg/dL)SterileTeicoplanin IV10Poor weight gain, jaundiceHigh serum bilirubin level (24.1 mg/dL), bigh serum bilirubin level (24.1 mg/dL)SterileTeicoplanin IV11JaundiceHigh serum bilirubin level (20.9 mg/dL).SterileCefotaxime IV + FR11JaundiceHigh serum bilirubin level (20.7 mg/dL)SterileTeicoplanin IV12JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV13Lethargy + iritability, jaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV14JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileCefotaxime IV18Poor itsue perfusion, jaundiceMetabolic acidosis (PH - 23.24)+CO3: 12.4), high serum bilirubin level (24.1 mg/dL)SterileCef	4	Jaundice		Sterile	Teicoplanin IV
jaundiceHigh serum bilirubin level (23.9 mg/dL)SterileTeicoplanin IV8Fever, jaundiceHigh Serum bilirubin level (23.9 mg/dL)SterileTeicoplanin IV9JaundiceHigh Serum bilirubin level (23.8 mg/dL)SterileTeicoplanin IV10Poor weight gain, jaundiceHigh Serum bilirubin level (23.8 mg/dL), highSterileTeicoplanin IV11JaundiceHigh Serum bilirubin level (23.8 mg/dL), highSterileCefotaxime IV + FR11JaundiceHigh Serum bilirubin level (28.9 mg/dL), highSterileTeicoplanin IV12JaundiceHigh Serum bilirubin level (20.0 mg/dL)SterileTeicoplanin IV13Lethargy + irritability, jaundiceHigh serum bilirubin level (20.7 mg/dL)SterileTeicoplanin IV14JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV20JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV20JaundiceHig	5	Jaundice	High serum bilirubin level (20.6 mg/dL)	Sterile	Cefotaxime IV
8Fever, jaundiceHigh CRP level (24.1 mg/dL), high //T ratio (0.4), high serum bilirubin level (17.4 mg/dL)SterileTeicoplanin IV9JaundiceHigh serum bilirubin level (23.3 mg/dL)SterileTeicoplanin IV10Poor weight gain, jaundiceHigh serum bilirubin level (23.3 mg/dL)SterileCefotaxime IV + FR11JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileCefotaxime IV + FR11JaundiceHigh serum bilirubin level (20 mg/dL)SterileTeicoplanin IV12JaundiceHigh serum bilirubin level (20 mg/dL)SterileTeicoplanin IV13Lethargy + irritability, aundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV14JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (19.6 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV19JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV <td>6</td> <td>0</td> <td>High serum bilirubin level (15.2 mg/dL)</td> <td>Sterile</td> <td>Cefotaxime IV</td>	6	0	High serum bilirubin level (15.2 mg/dL)	Sterile	Cefotaxime IV
9JaundiceHigh serum bilirubin level (17.4 mg/dL)SterileTeicoplanin IV10Poor weight gain, jaundiceHigh Serum bilirubin level (23.3 mg/dL), high serum bilirubin level (24.1 mg/dL)SterileCefotaxime IV + FR11JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileTeicoplanin IV12JaundiceHigh serum bilirubin level (20 mg/dL)SterileTeicoplanin IV13Lethargy + irritability, jaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV14JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (13.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.22/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL)SterileCefotaxime IV19JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV <t< td=""><td>7</td><td>Jaundice</td><td>High serum bilirubin level (23.9 mg/dL)</td><td>Sterile</td><td>Teicoplanin IV</td></t<>	7	Jaundice	High serum bilirubin level (23.9 mg/dL)	Sterile	Teicoplanin IV
10Poor weight gain, jaundiceHigh BUN/Cre (60 mg/dL/. 8 mg/dL), high serum bilirubin level (24.1 mg/dL)SterileCefotaxime IV + FR11JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileTeicoplanin IV12JaundiceHigh serum bilirubin level (20 mg/dL)SterileTeicoplanin IV13Lethargy + irritability, jaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV14JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (19.6 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (PI: 72.2/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL)SterileTeicoplanin IV + FR19JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (20.7 mg/dL)SterileCefotaxime IV <t< td=""><td>8</td><td>Fever, jaundice</td><td></td><td>Sterile</td><td>Teicoplanin IV</td></t<>	8	Fever, jaundice		Sterile	Teicoplanin IV
11JaundiceHigh serum bilirubin level (24.1 mg/dL)SterileTeicoplanin IV12JaundiceHigh serum bilirubin level (20 mg/dL)SterileTeicoplanin IV13Lethargy + irritability, jaundiceHigh serum bilirubin level (23.7 mg/dL)SterileTeicoplanin IV14JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (19.6 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pfl: 7.23/HCO3: 12.4), high serum bilirubin level (24.9 mg/dL)SterileTeicoplanin IV + FR19JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (23.7 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV25JaundiceHigh serum bilirubin level (20.7 mg/dL)SterileCefotaxime IV26JaundiceHigh serum bilirubin level (20	9	Jaundice	High serum bilirubin level (23.3 mg/dL)	Sterile	Teicoplanin IV
12JaundiceHigh serum bilirubin level (20 mg/dL)SterileTeicoplanin IV13Lethargy + irritability, jaundiceHigh serum bilirubin level (23.7 mg/dL)SterileTeicoplanin IV14JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL)SterileTeicoplanin IV + FR19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV26JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV27JaundiceHigh serum bilirubin level (23 mg/dL)<	10	Poor weight gain, jaundice		Sterile	Cefotaxime IV + FR
13Lethargy + irritability, jaundiceHigh serum bilirubin level (23.7 mg/dL)SterileTeicoplanin IV14JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (19.6 mg/dL)SterileCefotaxime IV16Diarrhea, jaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL)SterileTeicoplanin IV + FR19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV26JaundiceHigh serum bilirubin level (23 mg/dL) </td <td>11</td> <td>Jaundice</td> <td>High serum bilirubin level (18 mg/dL)</td> <td>Sterile</td> <td>Teicoplanin IV</td>	11	Jaundice	High serum bilirubin level (18 mg/dL)	Sterile	Teicoplanin IV
jaundice14JaundiceHigh serum bilirubin level (17.9 mg/dL)SterileCefotaxime IV15JaundiceHigh serum bilirubin level (19.6 mg/dL)SterileTeicoplanin IV16Diarrhea, jaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (21.9 mg/dL)SterileTeicoplanin IV + FR19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23.0 mg/dL)SterileCefotaxime IV25JaundiceHigh serum bilirubin level (23.0 mg/dL)SterileCefotaxime IV26JaundiceHigh serum bilirubin level (23.0 mg/dL)SterileCefotaxime IV27JaundiceHigh serum bilirubin level (23.0 mg/dL)SterileCefotaxime IV28JaundiceHigh serum bilirubin level (23.0 mg/dL)SterileCefotaxime IV29JaundiceHigh serum bilirubin level (23.0 m	12	Jaundice	High serum bilirubin level (20 mg/dL)	Sterile	Teicoplanin IV
15JaundiceHigh serum bilirubin level (19.6 mg/dL)SterileTeicoplanin IV16Diarrhea, jaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL)SterileTeicoplanin IV + FR19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileTeicoplanin IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	13	•••	High serum bilirubin level (23.7 mg/dL)	Sterile	Teicoplanin IV
16Diarrhea, jaundiceHigh serum bilirubin level (19.9 mg/dL)SterileCefotaxime IV17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL)SterileTeicoplanin IV + FR19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	14	Jaundice	High serum bilirubin level (17.9 mg/dL)	Sterile	Cefotaxime IV
17JaundiceHigh serum bilirubin level (21.4 mg/dL)SterileCefotaxime IV18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL)SterileTeicoplanin IV + FR19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileTeicoplanin IV20JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	15	Jaundice	High serum bilirubin level (19.6 mg/dL)	Sterile	Teicoplanin IV
18Poor tissue perfusion, jaundiceMetabolic acidosis (pH: 7.23/HCO3: 12.4), high serum bilirubin level (13.4 mg/dL)SterileTeicoplanin IV + FR19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileTeicoplanin IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh CRP level/leukocytosis (44.1 mg/dL/17 800/mm³), high serum bilirubin levelSterileCefotaxime IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	16	Diarrhea, jaundice	High serum bilirubin level (19.9 mg/dL)	Sterile	Cefotaxime IV
jaundicehigh serum bilirubin level (13.4 mg/dL)19JaundiceHigh serum bilirubin level (24.9 mg/dL)SterileTeicoplanin IV20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh CRP level/leukocytosis (44.1 mg/dL/17 800/mm³), high serum bilirubin level (17.3 mg/dL)SterileTeicoplanin IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	17	Jaundice	High serum bilirubin level (21.4 mg/dL)	Sterile	Cefotaxime IV
20JaundiceHigh serum bilirubin level (20.6 mg/dL)SterileCefotaxime IV21JaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh CRP level/leukocytosis (44.1 mg/dL/17 800/mm³), high serum bilirubin level (20.2 mg/dL)SterileTeicoplanin IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	18			Sterile	Teicoplanin IV + FR
21JaundiceHigh serum bilirubin level (18.4 mg/dL)SterileCefotaxime IV22Fever, jaundiceHigh CRP level/leukocytosis (44.1 mg/dL/17 800/mm³), high serum bilirubin level (20.2 mg/dL)SterileTeicoplanin IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	19	Jaundice	High serum bilirubin level (24.9 mg/dL)	Sterile	Teicoplanin IV
22Fever, jaundiceHigh CRP level/leukocytosis (44.1 mg/dL/17 800/mm³), high serum bilirubin level (20.2 mg/dL)SterileTeicoplanin IV23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	20	Jaundice	High serum bilirubin level (20.6 mg/dL)	Sterile	Cefotaxime IV
23JaundiceHigh serum bilirubin level (17.3 mg/dL)SterileCefotaxime IV24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	21	Jaundice	High serum bilirubin level (18.4 mg/dL)	Sterile	Cefotaxime IV
24JaundiceHigh serum bilirubin level (23 mg/dL)SterileCefotaxime IV25JaundicePyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL)SterileTeicoplanin IV	22	Fever, jaundice	800/mm ³), high serum bilirubin level	Sterile	Teicoplanin IV
25 Jaundice Pyuria (17 white blood cell per HPF), high serum bilirubin level (16.1 mg/dL) Sterile Teicoplanin IV	23	Jaundice	High serum bilirubin level (17.3 mg/dL)	Sterile	Cefotaxime IV
serum bilirubin level (16.1 mg/dL)	24	Jaundice	High serum bilirubin level (23 mg/dL)	Sterile	Cefotaxime IV
26 Jaundice High serum bilirubin level (19.5 mg/dL) Sterile Teicoplanin IV	25	Jaundice		Sterile	Teicoplanin IV
	26	Jaundice	High serum bilirubin level (19.5 mg/dL)	Sterile	Teicoplanin IV

Table 2. Detailed clinical signs and symptoms, laboratory abnormalities, and treatment modalities of newborns with both significant hyperbilirubinemia and urinary tract infection (n = 26).

Abbreviations: BUN, blood urea nitrogen; Cre, creatinine; CRP, C-reactive protein; FR, fluid replacement; HPF, high-power field; *I/T*, immature-to-total neutrophils; IV, intravenously.

^aCerebrospinal fluid cultures were not required after evaluating the newborn's general condition and other laboratory test results. Repeat (control) urine and blood cultures were obtained after completion of treatment.

Table 3. Comparison of demographic and laboratory characteristics of newborns with significant hyperbilirubinemia but without urinary tract infection (group I) and of newborns with both significant hyperbilirubinemia and urinary tract infection (group II).

PARAMETER	GROUP I (N = 129)	GROUP II (N = 26)	<i>P</i> VALUE
Gestational age, wk ^a	37.87 ± 1.56	37.85 ± 1.19	.946
Maternal age, y ^a	28.28 ± 5.0	29.92 ± 3.82	.065
Age on admission, h ^a	128.48 ± 75.58	127.73 ± 66.63	.963
Birth weight, gª	3131.47 ± 475.63	3336.15 ± 555.38	.054
Weight on admission, g ^a	2987 ± 458.1	3175.38 ± 494.14	.061
Weight loss on admission as percent (if present) ^a	5.08 ± 3.64	6.08 ± 5.26	.242
Serum total bilirubin, mg/dL ^{a,b}	18.25 ± 2.94	20.08 ± 2.99	.005
Serum direct bilirubin, mg/dL ^{a,b}	0.54 ± 0.13	0.69 ± 0.22	.001
Ratio of direct to total bilirubin levels ^a	0.02992 ± 0.00702	0.035188 ± 0.01581	.0024
Serum total bilirubin at the 24th hour of phototherapy, mg/dL ^{a,b}	8.83 ± 1.49	10.08 ± 1.42	.0001
Decrease in serum total bilirubin at 24th hour as percent	51.55 ± 4.01	49.61 ± 3.43	.022
Hemoglobin, g/dLª	17.54 ± 2.17	17.3 ± 2.3	.608
Hematocrit ^a	50.8 ± 6.56	50.1 ± 6.67	.594
Free T4, ng/dLª	1.8 ± 2.74	1.4 ± 0.2	.479
TSH, μIU/mLª	3.75 ± 1.8	3.68 ± 2.12	.868
Presence of pyuria (present/absent)	7/122	3/23	.223
Route of delivery (vaginal/cesarean)	52/78	10/16	.919
Sex (female/male)	69/60	3/23	.000
Enclosed hemorrhage (present/absent)	5/124	2/24	.33
Abnormal weight loss (present/absent)	7/122	2/24	.647
Feeding pattern			
Breast milk (%)	118 (91.47)	22 (84.61)	
Formula milk (%)	4 (3.1)	1 (3.84)	.094
Partially breast milk (%)	7 (5.42)	3 (11.53)	

^aValues are given as mean \pm SD.


^b1 mg/dL bilirubin = 17.1 μ mol/L bilirubin.


between the 2 groups regarding gestational age, maternal age, age on admission, birth weight, weight on admission, abnormal weight loss, hemoglobin and hematocrit levels, route of delivery, feeding pattern, and sex. However, serum total and direct bilirubin levels and ratio of direct to total bilirubin levels on admission and serum total bilirubin levels at the 24th hour of phototherapy were significantly higher in group II compared with group I (18.25 ± 2.94 vs 20.08 ± 2.99, P = .005; 0.54 ± 0.13 vs 0.69 ± 0.22, P = .001; 0.02992 ± 0.00702 vs 0.035188 ± 0.01581, P = .0024; and 8.83 ± 1.49 vs 10.08 ± 1.42, P = .0001, respectively) (Figure 1). Decrease in serum total bilirubin level at 24th hour calculated as

percent was significantly higher in group I compared with group II (51.55 \pm 4.01% vs 49.61 \pm 3.43%, *P* = .022) (Table 3; Figure 2).

Discussion

Although the pathophysiologic relationship between hyperbilirubinemia and UTI has not exactly been revealed, one of the suggested mechanisms is hemolysis caused by *E coli* and other gram-negative bacteria. Even little hemolysis in the newborn may cause significant hyperbilirubinemia due to immature conjugation mechanisms, and thus, serum bilirubin levels may increase as an alerting sign even in UTIs with mild clinical





severity. Conjugated hyperbilirubinemia associated with UTI may be related to cholestasis. Although how UTI causes cholestasis is not well defined, microcirculatory problems in liver and direct bacterial and endotoxin-mediated products are the other suggested mechanisms.¹⁶ However, some authors claim that the relationship between UTI and neonatal jaundice is just a coincidence.¹⁷

In studies investigating the etiologic role of UTI in neonatal jaundice, the incidence of UTI has been reported between 5.8% and 21%.^{2,5,6,9} Ghaemi et al⁹ have reported a 5.8% incidence of UTI in 400 newborns in a prospective study. Garcia and Nager⁵ have reported a UTI incidence of 7.5% in 160 infants of less than 8 weeks old with no other complaints other than jaundice. Bilgen et al² have reported a UTI incidence of 8% in 102 infants with jaundice. In their retrospective study, Omar et al⁶ have reported the highest (21%) incidence in 152 jaundiced infants. In our study, we detected the prevalence of UTI as 16.7% in 155 newborns with early jaundice in whom all other etiologic factors of significant neonatal hyperbilirubinemia were ruled out.

There are various ideas about the profile of microorganisms causing both jaundice and UTI. In a retrospective analysis of 120 asymptomatic jaundiced newborns, the most commonly detected (6 of 15) causative agent was *Klebsiella pneumoniae*.¹¹ In another retrospective study, the most common (5 of 12) causative agent was *E coli* in 217 asymptomatic jaundiced infants.⁴ In our study, the most commonly isolated agent was

Klebsiella spp. (8 of 26; 30.7%). However, geographical or environmental factors may contribute to bacteriologic and epidemiologic characteristics of UTI.

In infants with UTI, the prevalence of pyuria has reportedly been 58.3%, 52%, and 33% in 3 different studies, respectively.^{4,8,11} In our study, pyuria was present in 15.3% of 26 newborns with UTI.

Garcia and Nager⁵, in their study analyzing the association of neonatal jaundice and UTI, have reported that UTI was present in all the cases who had conjugated hyperbilirubinemia. Singh-Grewal et al¹⁸ have detected a stronger association with UTI due to *E coli* and conjugated hyperbilirubinemia compared with that of unconjugated hyperbilirubinemia. In our study, cases with both UTI and significant hyperbilirubinemia had significantly higher conjugated bilirubin levels and higher direct/total bilirubin ratio when compared with cases of group I who had significant hyperbilirubinemia without UTI.

In most of the studies investigating the relationship between UTI and neonatal jaundice, male sex was a significant risk factor compared with female sex in the neonatal period.^{8,9,19,20} In accordance with these studies reported, most of the cases (23 of 26) with both UTI and significant hyperbilirubinemia in our study were men. Ghaemi et al⁹ have reported that 60% of their male cases with UTI were not circumcised, and Singh-Grewal et al¹⁸ have reported that circumcision significantly reduces the risk of UTI. In another study, it has been reported that a high uropathogenic bacteria colonization is observed in uncircumcised newborns, and this increases UTI risk 10-fold.²¹ As all the newborns in our study were uncircumcised, we could not make a comparison regarding this. However, it has been well demonstrated that newborn circumcision results in a 9.1- to 9.9-fold decrease in incidence of UTI during the first year of life.^{22,23}

Garcia and Nager⁵ have reported that infants whose jaundice presents after 8 days of life have UTI very likely. In our study, jaundice had occurred in 84.6% of cases in the first 7 days of life. Similarly, Bilgen et al² have reported that most of their cases developed jaundice after the seventh day of life. This study differs from most of the other studies published as newborns with early-onset (\leq 7 days) jaundice were studied predominantly.

Ghaemi et al⁹ have reported that infants fed formula milk had a significantly higher risk of UTI compared with infants fed breast milk. Chen et al⁴ have also reported similar results. In this study, we did not detect a significant difference between the groups with and without UTI regarding feeding pattern.

In their study comparing jaundiced infants with and without UTI, Shahian et al¹¹ have detected no significant differences regarding serum bilirubin levels. Some other studies have reported significantly lower serum bilirubin levels in newborns with prolonged jaundice and UTI compared with those without UTI.^{3,24} In our study, however, serum bilirubin levels both on admission and at the 24th hour of phototherapy were statistically significantly higher in newborns with UTI and jaundice compared with those with jaundice but without UTI.

In our study design, we tested the efficacy of phototherapy by measuring and comparing the serum bilirubin levels at 24th hour. We found that response to phototherapy in terms of serum bilirubin decrease was lower in newborns with both UTI and jaundice compared with those with jaundice but without UTI. Poor phototherapy response similar to that observed in hemolytic hyperbilirubinemias is interesting; this may have also resulted from statistically significantly increased serum direct bilirubin levels and direct to total bilirubin ratio, and thus, the possibility of UTI should be considered in jaundiced (especially conjugated) newborns who do not respond to phototherapy well or have a prolonged duration of phototherapy treatment.

As a conclusion, UTI should be routinely investigated in early (≤ 10 days) idiopathic neonatal jaundice in which all other etiologic factors of neonatal hyperbilirubinemia are ruled out, and the presence of UTI should be considered in case of a poor phototherapy response in cases receiving phototherapy.

Author Contributions

Concept: MO and SUS. Design: MO and SUS. Supervision: MAS and DS. Materials: YY and MA. Data collection and/or processing: DA and BO. Analysis and/or interpretation: SUS and MAS. Literature review: MO and SUS. Writing: MO and SUS.

REFERENCES

- Linder N, Yatsiv I, Tsur M, et al. Unexplained neonatal jaundice as an early diagnostic sign of septicemia in the newborn. *J Perinatol.* 1988;8:325–327.
- Bilgen H, Ozek E, Unver T, Biyikli N, Alpay H, Cebeci D. Urinary tract infection and hyperbilirubinemia. *Turk J Pediatr.* 2006;48:51–55.
- Nickavar A, Sotoudeh K. Treatment and prophylaxis in pediatric urinary tract infection. *Int J Prev Med.* 2011;2:4–9.
- Chen HT, Jeng MJ, Soong WJ, et al. Hyperbilirubinemia with urinary tract infection in infants younger than eight weeks old. J Chin Med Assoc. 2011;74: 159–163.

- Garcia FJ, Nager AL. Jaundice as an early diagnostic sign of urinary tract infection in infancy. *Pediatrics*. 2002;109:846–851.
- Omar C, Hamza S, Bassem AM, Mariam R. Urinary tract infection and indirect hyperbilirubinemia in newborns. NAm J Med Sci. 2011;3:544–547.
- Pashapour N, Nikibahksh AA, Golmohammadlou S. Urinary tract infection in term neonates with prolonged jaundice. Urol J. 2007;4:91–94.
- Rashed YK, Khtaband AA, Alhalaby AM. Hyperbilirubinemia with urinary tract infection in infants younger than eight weeks old. *J Pediatr Neonatal Care*. 2014;1:00036.
- Ghaemi S, Fesharaki RJ, Kelishadi R. Late onset jaundice and urinary tract infection in neonates. *Indian J Pediatr.* 2007;74:139–141.
- Mutlu M, Çayır Y, Aslan Y. Urinary tract infections in neonates with jaundice in their first two weeks of life. *World J Pediatr.* 2014;10:164–167.
- Shahian M, Rashtian P, Kalani M. Unexplained neonatal jaundice as an early diagnostic sign of urinary tract infection. *Int J Infect Dis.* 2012;16:e487–e490.
- American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics*. 2004;114:297–316.
- Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant ≥35 weeks' gestation: an update with clarifications. *Pediatrics*. 2009;124:1193–1198.
- Wong RJ, Bhutani VK. Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn. In: Abrams SA, Rand EB eds. UpToDate. Waltham, MA: UpToDate; 2015. www.uptodate.com/contents/pathogenesis-and-etiology-of-unconjugated-hyperbilirubinemia-in-the-newborn. Accessed August 17, 2016.
- Stein R, Dogan HS, Hoebeke P, et al; European Association of Urology; European Society for Pediatric Urology. Urinary tract infections in children: EAU/ESPU guidelines. *Eur Urol.* 2015;67:546–558.
- 16. Kasap B, Soylu A, Kavukçu S. Relation between hyperbilirubinemia and urinary tract infections in the neonatal period. *J Nephrol Therapeutic*. 2014;S11:009.
- Sarici SÜ, Kul M, Alpay F. Neonatal jaundice coinciding with or resulting from urinary tract infections? *Pediatrics*. 2003;112:1212–1213.
- Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. *Arch Dis Child*. 2005;90:853–858.
- Lee HC, Fang SB, Yeung CY, Tsai JD. Urinary tract infections in infants: comparison between those with conjugated vs unconjugated hyperbilirubinaemia. *Ann Trop Paediatr.* 2005;25:277–282.
- Chang SL, Shortliffe LD. Pediatric urinary tract infections. *Pediatr Clin North* Am. 2006;53:379–400.
- Zorc JJ, Levine DA, Platt SL, et al. Clinical and demographic factors associated with urinary tract infection in young febrile infants. *Pediatrics*. 2005;116: 644–648.
- Schoen EJ, Colby CJ, Ray GT. Newborn circumcision decreases incidence and costs of urinary tract infections during the first year of life. *Pediatrics*. 2000;105:789–793.
- Morris BJ, Wiswell TE. Circumcision and lifetime risk of urinary tract infection: a systematic review and meta-analysis. J Urol. 2013;148:2118–2124.
- Abourazzak S, Bouharrou A, Hida M. [Jaundice and urinary tract infection in neonates: simple coincidence or real consequence?]. *Arch Pediatr.* 2013;20: 974–978.